Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-03-18
2008-03-18
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S016700, C514S017400, C530S300000, C530S327000, C530S329000
Reexamination Certificate
active
10666095
ABSTRACT:
Novel peptides are disclosed that may be used as inhibitors of amyloidogenesis, as suppressors of amyloid toxicity, and as therapeutic agents for amyloid-associated diseases such as Alzheimer's disease, Parkinson's Disease, Creutzfeldt-Jakob Disease, Huntington's Disease, and Type II Diabetes. These new β-strand mimics (β-sheet “blockers”), containing Cα,α-disubstituted amino acids, specifically interact with and block the development of the β-sheet structure of the developing fibrils of amyloid diseases, such as Alzheimer's disease amyloid β-peptide (Aβ). We have discovered that oligomerization of β-sheet structures, including those implicated in amyloid-associated diseases, may be inhibited or even reversed by the presence of extended peptide structures that have only one edge available for hydrogen bonding. Without a second edge that is also available for hydrogen bonding, the extension of a developing β-sheet is blocked by binding to the novel peptides.
REFERENCES:
patent: 5854204 (1998-12-01), Findeis et al.
patent: 6277826 (2001-08-01), Findeis et al.
patent: 6566334 (2003-05-01), McLaughlin et al.
patent: 6689753 (2004-02-01), Soto-Jara
Conway et al. Emerging Beta-Amyloid Therapies for the Treatment of Alzheimer's Disease. Current Pharmaceutical Design. 2003, vol. 9, pp. 427-447.
H. LeVine. The Challenge of Inhibiting A-Beta Polymerization. Current Medicinal Chemistry. 2002, vol. 9, pp. 1121-1133.
Aucoin, J., “Determination of Possible Surface Adsorption of Beta-Amyloid Aggregate Species and Aggregation Inhibition Products Using Scanning Force Microscopy and Dynamic Light Scattering,” Presentation at National Meeting of the American Chemical Society (Aug. 18, 2002).
Aucoin, J., “Dissection of an Amyloid Aggregation Inhibitor,” presentation at 225th American Chemical Society conference (Mar. 23-27, 2003).
Aucoin, J., “Interplay between beta-Amyloid (1-40) and a Peptide-based beta-Amyloid Aggregation Inhibitor,” presentation at 225th American Chemical Society conference (Mar. 23-27, 2003).
Aucoin, J. et al., “Surface and Solution Studies of Beta-Amyloid Aggregation using Dynamic Light Scattering and Atomic Force Microscopy,” Presentation at Pittsburgh Conference (Sep. 17, 2002).
Fu, “Facile Synthesis of Sterically Hindered α,α-Disubstituted Amino Acids and Their Incorporation into Peptides by Solid-Phase Peptide Synthesis,”Presentation at 222nd National Meeting of the American Chemical Society (Aug. 26, 2001).
Fu, Y., “Artificial Peptides Containing Cα,α-Disubstituted Amino Acids: Synthesis, Conformational Studies, and Application as β-Strand Mimics,” PhD Dissertation, Louisiana State University (Baton Rouge, LA, submitted Dec. 2002).
Fu, Y. et al., “Efficient Acylation of theN-Terminus of Highly Hindered Cα,α-Disubstituted Amino Acids via Amino Acid Symmetrical Anhydrides,”Org. Lett., vol. 4, pp. 237-240 (2002).
Fu, Y. et al., “Sterically Hindered Cα,α-Disubstituted α-Amino Acids: Synthesis from α-Nitroacetate and Incorporation into Peptides,”J. Org. Chem., vol. 66, pp. 7118-7124 (2001).
Hammer, R. et al., “β-Strand Mimics as Fibrillogenesis Inhibitors,” Excerpt from grant proposal submitted to National Institutes of Health (1999).
Pallitto, M. et al., “Recognition sequence design for peptidyl modulators of β-amyloid aggregation and toxicity,”Biochem., vol. 38, pp. 3570-3578 (1999).
Toniolo, C. et al., “Control of peptide conformation by the Thorpe-Ingold effect (Cα-tetrasubstitution),”Biopolymers, vol. 60, pp. 396-419 (2001, or 2002).
Wilcock, D. et al., “Intracranially administered anti-Aβ antibodies reduce β-amyloid deposition by mechanisms both independent of and associated with microglial activation,” J. Neurosci., vol. 23, pp. 3745-3751 (2003).
Wysong, C. et al., “4-Aminopiperidine-4-carboxylic acid: A cyclic alpha, alpha-disubstitued amino acid for preparation of water-soluble highly helical peptides,”J. Org. Chem., vol. 61, pp. 7650-7651 (1996).
Aucoin, J., “Interplay between beta-Amyloid (1-40) and a Peptide-based beta-Amyloid Aggregation Inhibitor,” abstract of presentation at 225th American Chemical Society conference (Mar. 23-27, 2000).
H. Ikeda et al., “Genome sequence of an industrial microorganismStreptomyces avermitilis: Deducing the ability of producing secondary metabolites,” Proc. Natl. Acad. Sci. (USA), vol. 98, pp. 12215-12220 (2001).
Fu Yanwen
Hammer Robert P.
McLaughlin Mark L.
Miller Tod J.
Board of Supervisors of Louisiana State University and Agricultu
Davis Bonnie J.
Runnels John H.
Russel Jeffrey Edwin
LandOfFree
Anti-fibril peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-fibril peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-fibril peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3933093